SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes.

SurgiMend is specifically indicated for:

· Plastic and reconstructive surgery
· Muscle flap reinforcement
· Hernia repair including abdominal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias.

Device Description

SurgiMend is an acellular dermal tissue derived from bovine dermis. The device is available in solid, fenestrated, and perforated configurations. The device is supplied sterile in a variety of sizes, shapes, and thicknesses.

AI/ML Overview

The provided text is a 510(k) Premarket Notification for a medical device (SurgiMend MP Collagen Matrix for Soft Tissue Reconstruction), seeking substantial equivalence to a predicate device. It is a regulatory document and does not describe a study involving an AI/Machine Learning device or a diagnostic product that would require acceptance criteria in the sense of performance metrics (like sensitivity, specificity, accuracy) typically associated with AI models or diagnostic tests.

Instead, the "acceptance criteria" and "study" described in this document relate to the physicochemical, mechanical, and biological properties of the medical mesh device itself, and the "study" is a comparison to a predicate device to demonstrate substantial equivalence for regulatory approval.

Therefore, many of the requested items in the prompt (e.g., sample size for test set, data provenance, number of experts for ground truth, MRMC study, standalone performance, training set details) are not applicable (N/A) to this type of device and regulatory submission.

However, I can extract and present the information that is relevant to the document provided, reinterpreting "acceptance criteria" and "study" within the context of a medical device 510(k) submission for a surgical mesh.

Device: SurgiMend® MP Collagen Matrix for Soft Tissue Reconstruction

Type of Device: Surgical Mesh (Class II)

Purpose of Submission (510(k)): To demonstrate substantial equivalence to a legally marketed predicate device (SurgiMend® Collagen Matrix for Soft Tissue Reconstruction, K083898).

Here's an interpretation of the requested information based on the provided document:

1. A table of acceptance criteria and the reported device performance:

Acceptance Criteria (Demonstrated Equivalence to Predicate)	Reported Device Performance (SurgiMend MP)
Design: Same as predicate.	Same design as predicate, with an additional "perforated configuration" (holes 2-3 mm diameter in a staggered array) allowing for better fluid flow. The core design (acellular bovine dermis) remains unchanged.
Material: Same as predicate.	Same materials (acellular dermal tissue derived from bovine dermis) as predicate.
Manufacturing Process: Same as predicate.	Same manufacturing process as predicate.
Packaging & Sterilization: Same as predicate.	Same packaging and sterilization parameters as predicate.
Biocompatibility: Safe for use.	Biocompatibility testing conducted on the predicate device (K083898) confirms the biological safety of SurgiMend MP. (Implies SurgiMend MP is expected to have the same biocompatibility profile due to identical materials and processing).
Mechanical Properties: Equivalent to predicate; compliant with FDA Guidance for Surgical Mesh.	Mechanical testing (tensile strength, suture pull-out, tear resistance, and ball burst) were conducted. All test results were acceptable and complied with FDA Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh, March 2, 1999. (Implies performance similar to or within acceptable ranges of the predicate).
In Vivo Performance (Reinforcement, Revascularization, Tissue Integration): Basic properties unchanged from predicate after implantation.	Implantation studies were conducted in three different animal models (12-week rat hernia repair, 4-week rat intra-abdominal, 2-week rat intra-muscle implant).Primary Endpoint: Mechanical strength to support soft tissue reinforcement.Secondary Endpoints: Revascularization and tissue integration of perforated test and non-perforated control configurations.Result: Studies demonstrated "the basic properties of the subject device after implantation remain unchanged from the predicate."
Indended Use: Equivalent to predicate.	Same Indications for Use as the predicate: implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes, specifically for plastic and reconstructive surgery, muscle flap reinforcement, and hernia repair (abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias). The minor modification (perforations) does not change intended use.
Safety & Effectiveness: No new issues raised.	The modifications do not change the intended use, nor alter the fundamental scientific technology of the device, and do not raise any new issues of safety and effectiveness.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):

Test Set Sample Size: No specific numerical sample size for "test sets" in the context of an AI model is provided. This document refers to pre-clinical studies (animal models) and mechanical testing of the device itself.
- Mechanical Testing: Not specified, but implied to be sufficient for compliance with FDA guidance.
- Animal Implantation Studies: "three different animal models" were used (rat hernia repair, rat intra-abdominal, rat intra-muscle implant). The number of animals per model is not specified.
Data Provenance: Not specified, but implied to be from studies conducted by or for TEI Biosciences Inc. (now Integra LifeSciences Corporation), located in the USA. These are pre-clinical (animal) studies, not human retrospective/prospective data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

N/A. This is not an AI/diagnostic device requiring expert ground truth for image interpretation or diagnosis. The "ground truth" for this device's performance relates to its physical, mechanical, and biological properties as measured in laboratory and animal studies, not human expert consensus on images.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

N/A. Not applicable to this type of device testing.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

N/A. This is a surgical mesh, not an AI-assisted diagnostic tool. No MRMC study was conducted.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

N/A. This is a physical medical device, not an algorithm.

7. The type of ground truth used (expert concensus, pathology, outcomes data, etc):

For mechanical performance: The "ground truth" is established by direct physical measurements according to specified ASTM/ISO standards and compliance with FDA guidance for surgical mesh, likely verified by internal quality control.
For biocompatibility: The "ground truth" is established by standard biocompatibility testing protocols, referencing the predicate device's confirmed biological safety.
For in vivo performance: The "ground truth" is established through direct observation and measurement in animal models (e.g., assessing mechanical strength of repair, revascularization, tissue integration post-implantation). This would involve histological analysis and biomechanical testing of harvested tissues.

8. The sample size for the training set:

N/A. This is not an AI/ML device, so there is no training set in that context. The "training" in this context would be the predicate device's historical performance data.

9. How the ground truth for the training set was established:

N/A. As above, no training set for an AI model. The "ground truth" for the predicate device's established safety and effectiveness would have been based on its own prior regulatory approvals, mechanical testing, biocompatibility studies, and potentially human clinical experience that led to its initial market clearance.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, overlaid on three human profiles facing to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

February 16, 2017

Integra LifeSciences Corporation c/o Ms. Kavita Amin Specialist, Regulatory Affairs 311 Enterprise Drive Plainsboro, New Jersey 08536

Re: K162965

Trade/Device Name: SurgiMend MP Collagen Matrix for Soft Tissue Reconstruction Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh Regulatory Class: Class II Product Code: FTM Dated: January 13, 2017 Received: January 17, 2017

Dear Ms. Amin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Jennifer R. Stevenson -S

For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K162965

Device Name

SurgiMend® MP Collagen Matrix for Soft Tissue Reconstruction

Indications for Use (Describe)

SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes.

SurgiMend is specifically indicated for:

· Plastic and reconstructive surgery
· Muscle flap reinforcement
· Hernia repair including abdominal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias.

Type of Use (Select one or both, as applicable)
-------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY

SurgiMend MP Collagen Matrix for Soft Tissue Reconstruction

Submitter's name and address:

TEI Biosciences Inc. 7 Elkins Street Boston, MA 02127 USA

Contact person and telephone number:

Kavita Amin Specialist, Regulatory Affairs Telephone: 609-750-7827

Date the Summary was prepared: 13 January 2017

Name of the device:

Trade name:	SurgiMend® MP Collagen Matrix for Soft TissueReconstruction
Common Name:	Surgical Mesh
Classification Name:	Mesh, Surgical (21 CFR 878.3300)
Product Code:	FTM

Predicate Device:

SurgiMend® MP is substantially equivalent in function and intended use to its predicate device as detailed in Table 1.

Table 1: Predicate Device

510(k)Number	ProductCode	Trade Name	Manufacturer
K083898	FTM	SurgiMend® Collagen Matrix forSoft Tissue Reconstruction	TEI BiosciencesInc.

Device Description:

Indication for Use:

SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes:

SurgiMend is specifically indicated for:

Plastic and reconstructive surgery ●
Muscle flap reinforcement ●
Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, ● umbilical, and incisional hernias.

{4}------------------------------------------------

Substantial Equivalence Comparison:

The modified device, SurgiMend MP, utilizes the same design, material, manufacturing process, packaging and sterilization parameters as the predicate device (K083898). The proposed device, SurgiMend MP, is offered in perforated configuration with holes of 2-3 mm in diameter in a staggered array. The addition of defined holes in this new configuration allows for better fluid flow through the device upon implantation.

Testing and Test Results:

The modified device, SurgiMend MP, is comprised of the same materials, processed, packaged and sterilized by the same method as the predicate device (K083898). The biocompatibility testing conducted on SurgiMend Collagen Matrix for Soft Tissue Reconstruction (K083898) product confirms the biological safety of the SurgiMend MP.

Performance testing for SurgiMend MP is the same as the predicate device. Mechanical testing, including tensile strength, suture pull-out, tear resistance, and ball burst were conducted in compliance with FDA Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh, March 2, 1999. All test results were acceptable.

The implantation studies were conducted in three different animal models (12 week rat hernia repair study, 4 week rat intra-abdominal, 2 week rat intra-muscle implant model) with the primary endpoint of mechanical strength to support soft tissue reinforcement. The studies also also characterized secondary endpoints of revascularization and tissue integration of perforated test and non-perforated control configurations. These studies demonstrate the basic properties of the subject device after implantation remain unchanged from the predicate. The result demonstrates the subject device is substantially equivalent to the predicate device.

Conclusion:

The modified device, SurgiMend MP, is substantially equivalent to the commercially available marketed device. SurgiMend. The modifications expressed in this 510(k) Premarket Notification do not change the intended use, nor alter the fundamental scientific technology of the device, and do not raise any new issues of safety and effectiveness.

Regulation Number and Section

§ 878.3300 Surgical mesh.

(a)
Identification. Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.(b)
Classification. Class II.